ObsEva SA (OBSV)
| Market Cap | 256.16M |
| Revenue (ttm) | 16,000 |
| Net Income (ttm) | -108.79M |
| Shares Out | 45.48M |
| EPS (ttm) | -1.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $3.90 |
| Previous Close | $3.85 |
| Change ($) | 0.05 |
| Change (%) | 1.30% |
| Day's Open | 3.94 |
| Day's Range | 3.82 - 4.03 |
| Day's Volume | 1,487,194 |
| 52-Week Range | 1.63 - 6.30 |
Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.
There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.
A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.
Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.
ObsEva (OBSV) stock is soaring higher on Friday as shares see heavy trading despite there not being any noteworthy news today. The post OBSV Stock: 7 Things for ObsEva Investors to Know Before...
In the last round, 36% of recipients saved the money, If you're planning the same with the second payment, here are seven stocks to buy with your stimulus check. The post 7 Stocks to Buy With ...
Geneva, Switzerland and Boston, MA – January 7, 2021 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's repro...
Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improv...
PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT])
Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impro...
ObsEva (OBSV) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids
Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy
Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impr...
Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impr...
Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to impr...
Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's ...
Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's r...
ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Lou...
GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercial...
Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s r...
Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids
Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s rep...
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24
ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will pres...
ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise ...
Geneva, Switzerland and Boston, MA – June 9, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel ...
GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproduc...
ObsEva Has A Promising Candidate For An Unmet Need - Behind The Idea
ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financia...
ObsEva (OBSV) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Geneva, Switzerland and Boston, MA – Tuesday 14, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization...
Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s rep...
GENEVA, Switzerland and BOSTON, MA (March 23, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s repro...
ObsEva's (OBSV) CEO Ernest Loumaye on Q4 2019 Results - Earnings Call Transcript
Wall Street analysts recommend increasing holdings in EQT Corporation (NYSE:EQT) and ObsEva SA (NASDAQ:OBSV), even though their share prices have dropped more than 59% in the past year through...
Shares of ObsEva gained 22% in premarket trading on the news that the company' s experimental treatment for women with uterine fibroids met its primary and secondary endpoints in a Phase 3 tr...
ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.
ObsEva SA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
ObsEva SA (OBSV) delivered earnings and revenue surprises of 23.17% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that the Phase 3 clini...
Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of no...
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids w...
Geneva, Switzerland and Boston, MA – October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization o...
Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of n...
About OBSV
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatme... [Read more...]
| Industry Biotechnology | IPO Date Jan 26, 2017 |
| CEO Ernest Loumaye | Employees 53 |
| Stock Exchange NASDAQ | Ticker Symbol OBSV |
Analyst Forecasts
According to 6 analysts, the average rating for ObsEva stock is "Buy." The 12-month stock price forecast is 11.67, which is an increase of 199.23% from the latest price.